Medicinova Inc   (MNOV)
Other Ticker:  
Price: $1.3500 $0.00 0.000%
Day's High: $1.39 Week Perf: 3.85 %
Day's Low: $ 1.33 30 Day Perf: -4.26 %
Volume (M): 81 52 Wk High: $ 2.66
Volume (M$): $ 109 52 Wk Avg: $2.00
Open: $1.36 52 Wk Low: $1.26

 Market Capitalization (Millions $) 98
 Shares Outstanding (Millions) 72
 Employees 8
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Medicinova Inc
Medicinova Inc. is a biopharmaceutical company headquartered in La Jolla, California. The company is focused on the development and commercialization of innovative therapeutics for the treatment of serious diseases with high unmet medical needs.

Medicinova was founded in 2000 by Dr. Yuichi Iwaki, and has since grown to become a leading player in the field of biopharmaceutical research and development. The company's research projects are primarily focused on developing therapeutics for the treatment of neurological and autoimmune diseases, with an emphasis on neurological disorders such as multiple sclerosis and neurological pain.

Among their most notable products is MN-166 (ibudilast), which has shown promising results in the treatment of a range of neurological disorders, including multiple sclerosis, neuropathic pain, and addiction. Medicinova also has a pipeline of other promising drug candidates, including MN-001 (tipelukast) for the treatment of nonalcoholic steatohepatitis (NASH) and MN-221 (bedoradrine), a selective beta-2 adrenergic receptor agonist for the treatment of acute exacerbations of asthma.

Since its founding, Medicinova has maintained a strong commitment to advancing the development of safe and effective therapeutics for the treatment of debilitating diseases. The company has received numerous awards for its contributions to the biopharmaceutical industry, including the Frost & Sullivan Global Product Line Strategy Leadership Award for MS Therapeutics in 2018.

Medicinova's team of scientists, researchers, and industry experts are driven by a shared commitment to achieving breakthroughs in the treatment of serious diseases, making the company a leader in the biopharmaceutical space.

   Company Address: 4275 Executive Square La Jolla 92037 CA
   Company Phone Number: 373-1500   Stock Exchange / Ticker: NASDAQ MNOV


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Medicinova Inc

Medicinova Inc Discloses Impressive Third Quarter Revenue Surpassing $1 Million Milestone

Medicinova Inc, a biopharmaceutical company, recently disclosed impressive financial results for the third quarter of 2023. Despite the prevailing economic challenges faced by many industries, Medicinova Inc managed to achieve a substantial revenue of $1 million during this period. This is a significant improvement compared to the same quarter in the previous year, where the company recorded a net loss of $-0.723 million, a notable reduction from the deficit of $-3.652 million.
These promising financial results demonstrate Medicinova Inc's ability to adapt and thrive in a competitive market. The company's innovative strategies and relentless dedication to research and development have paid off, as evidenced by these impressive earnings. It is important to note that such financial achievements are particularly remarkable, considering the adverse conditions experienced by many businesses due to the global pandemic.

Medicinova Inc

Medicinova Inc Shows Promising Progress Despite Operating Loss, Sets Stage for Future Success in Pharmaceutical Industry

Medicinova Inc, a major player in the Pharmaceutical Preparations sector, recently released its financial results for the second quarter of 2023. While the company reported an operating loss of $-3.30003 million, it is evident that Medicinova has made significant progress compared to the same period last year, where it recorded an operating loss of $-4.089935 million. This financial improvement positions Medicinova as a potential standout in the competitive Healthcare sector. Let us explore how these financial results may impact the company's future prospects.
1. Reduction in Operating Loss:
The most noteworthy aspect of Medicinova's financial results is the reduction in operating losses. Comparing the second quarter of 2023 to the same period in 2022, the company managed to decrease its losses from $-4.029 million to $-2.872 million. This significant reduction demonstrates Medicinova's commitment to improving its financial performance and suggests that the company's operational efficiency has improved.

Medicinova Inc

A Closer Look Into Pharmaceutical Industry's Latest Business Developments

The pharmaceutical industry is always on the lookout for the latest business developments and financial performances of companies operating in the sector. One such company is Medicinova Inc, which has recently come under the scanner of industry veterans. The first quarter results for 2023 have been released, and the company has reported an operating loss of $-2.963243 million. What is interesting is that no top-line has been specified by the company so far.
Upon closer inspection, it has been noted that Medicinova Inc has operated more efficiently as compared to the first quarter of 2022, when the operating loss was $-3.410012 million. This indicates that the company is making progress in developing its business model, and has succeeded in reducing its losses for the financial time-frame ending March 31, 2023 to $-2.918 million. This is an improvement from the $-3.386 million loss in the first quarter of 2022.


Medicinova Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com